#dialysis

The device may be approved for clinical use within the next three years.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.

In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.

Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.

This is according to a large study of Swedish people with hep C and chronic kidney disease.

And can treating the virus reduce the risk of chronic kidney and cardiovascular diseases as well as the risk of death from such causes?